Andrew Satlin

9.4k citations

103 papers · 6.9k indexed · 1 hit paper · h-index 45

Impact in

Endocrine and Autonomic Systems top 0.5%
- Circadian rhythm and melatonin
Psychiatry and Mental health top 0.5%
- Dementia and Cognitive Impairment Research

Papers in

Biological Psychiatry 15
- Tryptophan and brain disorders 15
Psychiatry and Mental health 35
- Dementia and Cognitive Impairment Research 15
- Bipolar Disorder and Treatment 11
- Schizophrenia research and treatment 10

Co-authors: Ladislav Volicer David G. Harper Edward G. Stopa Rachel Goldstein Ann C. McKee Hui Fang Perry F. Renshaw J. Alex Becker
Journals: Alzheimer s & Dementia (10 papers)American Journal of Psychiatry (8 papers)Schizophrenia Bulletin (6 papers)American Journal of Geriatric Psychiatry (5 papers)CNS Spectrums (5 papers)
Partner nations: United States United Kingdom Sweden

In The Last Decade

Andrew Satlin

102 papers receiving 6.6k citations

Hit Papers

align trajectories log scale

Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease 1997 · 528 citations

Peers

Countries citing papers authored by Andrew Satlin

Since Specialization

Citations

This map shows the geographic impact of Andrew Satlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Satlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Satlin more than expected).

Fields of papers citing papers by Andrew Satlin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Satlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Satlin. The network helps show where Andrew Satlin may publish in the future.

Co-authors

The 25 scholars most cited alongside Andrew Satlin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andrew Satlin Line = papers co-authored together Andrew Satlin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Adjunctive lumateperone (ITI‐007) in the treatment of bipolar depression: Results from a randomized placebo‐controlled clinical trial Bipolar Disorders ·Trisha Suppes, Suresh Durgam, J.H. LECK, Richard Chen, Hassan Lakkis, Robert E. Davis, Andrew Satlin, Kimberly E. Vanover, Sharon Mates, Roger S. McIntyre, Mauricio Tohen	2023	16
2	Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial American Journal of Psychiatry ·Joseph R. Calabrese, Suresh Durgam, Andrew Satlin, Kimberly E. Vanover, Robert E. Davis, Richard Chen, J.H. LECK, Sharon Mates, Roy H. Perlis	2021	65
3	Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia Schizophrenia Research ·Christoph U. Correll, Kimberly E. Vanover, Robert E. Davis, Richard Chen, Andrew Satlin, Sharon Mates	2021	23
4	Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study Journal of Clinical Sleep Medicine ·Patricia Murphy, Margaret Moline, David Mayleben, Russell Rosenberg, Gary Zammit, Kate Pinner, Shobha Dhadda, Quan Hong, Luigi Giorgi, Andrew Satlin	2017	119
5	Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody Alzheimer s Research & Therapy ·Veronika Logovinsky, Andrew Satlin, Robert Lai, Chad J. Swanson, June Kaplow, Gunilla Osswald, Hans Basun, Lars Lannfelt	2016	212
6	ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials Journal of Neurology Neurosurgery & Psychiatry ·Jinping Wang, Veronika Logovinsky, Suzanne Hendrix, L. J. Li, Carlos Perdomo, Lu Xu, Shobha Dhadda, Holzer Patrik, Martin Rabe, Johan Luthman, Jeffrey L. Cummings, Andrew Satlin	2016	115
7	Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease BMC Neurology ·Martin R. Farlow, Felix Veloso, Margaret Moline, Jane Yardley, Elimor Brand‐Schieber, Francesco Bibbiani, Heng Zou, Timothy Hsu, Andrew Satlin	2011	65
8	Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study Clinical Therapeutics ·Martin R. Farlow, Stephen Salloway, Pierre N. Tariot, Jane Yardley, Margaret Moline, Qin Wang, Elimor Brand‐Schieber, Heng Zou, Timothy Hsu, Andrew Satlin	2010	149
9	Dorsomedial SCN neuronal subpopulations subserve different functions in human dementia Brain ·David G. Harper, E. G. Stopa, V. Kuo-LeBlanc, Ann C. McKee, K Asayama, Ladislav Volicer, N. W. Kowall, Andrew Satlin	2008	126
10	Psychosis of Alzheimer's disease: Gender differences in regional perfusion Neurobiology of Aging ·Erin K. Moran, J. Alex Becker, Andrew Satlin, In Kyoon Lyoo, Alan J. Fischman, Keith A. Johnson	2007	25
11	Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial The Lancet ·Suzanne Oparil, Steven A. Yarows, Samir Patel, Hui Fang, Jack Zhang, Andrew Satlin	2007	325
12	Aliskiren, an Orally Effective Renin Inhibitor, Provides Antihypertensive Efficacy Alone and in Combination With Valsartan American Journal of Hypertension ·James L. Pool, R. Schmieder, Michel Azizi, Jean‐Claude Aldigier, Andrzej Januszewicz, Walter Zidek, Souhila Idris Bahloul, Andrew Satlin	2006	180
13	In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease Progress in Neuro-Psychopharmacology and Biological Psychiatry ·Blaise B. Frederick, In Kyoon Lyoo, Andrew Satlin, Mansi Singal, M. Justin Kim, Deborah Yurgelun‐Todd, Bruce M. Cohen, Perry F. Renshaw	2004	42
14	Sundowning and Circadian Rhythms in Alzheimer’s Disease American Journal of Psychiatry ·L. Volicer, David G. Harper, Gerardo Martín González, Rachel Goldstein, Andrew Satlin	2001	279
15	Pathologic Evaluation of the Human Suprachiasmatic Nucleus in Severe Dementia Journal of Neuropathology & Experimental Neurology ·Edward G. Stopa, Ladislav Volicer, V. Kuo-LeBlanc, David G. Harper, Adriana Álvarez, Barbara Tate, Andrew Satlin	1999	211
16	Regional atrophy of the corpus callosum in subjects with Alzheimer's disease and multi-infarct dementia Psychiatry Research Neuroimaging ·In Kyoon Lyoo, Andrew Satlin, Chang Kyun Lee, Perry F. Renshaw	1997	59
17	Late-Life Suicide: A Review Harvard Review of Psychiatry ·Ashok J. Bharucha, Andrew Satlin	1997	17
18	Depression in a Long‐Term Care Facility: Clinical Features and Discordance Between Nursing Assessment and Patient Interviews Journal of the American Geriatrics Society ·Adam B. Burrows, Andrew Satlin, Carl Salzman, Tasuku TOGASHI, Lewis A. Lipsitz	1995	62
19	Prevalence and severity of akathisia in patients on clozapine Biological Psychiatry ·Bruce M. Cohen, Paul E. Keck, Andrew Satlin, Jonathan Cole	1991	61
20	Vitamin B12 and folate status in acute geropsychiatric inpatients: Affective and cognitive characteristics of a vitamin nondeficient population Biological Psychiatry ·Iris R. Bell, Joel S. Edman, David W. Marby, Andrew Satlin, Milo Westler, Benjamin Liptzin, Jonathan Cole	1990	91

About Andrew Satlin

Andrew Satlin is a scholar working on Biological Psychiatry, Psychiatry and Mental health, Endocrine and Autonomic Systems, Aging and Pharmacology, having authored 103 papers that have together received 6.9k indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (17 papers), Dementia and Cognitive Impairment Research (15 papers), Tryptophan and brain disorders (15 papers), Circadian rhythm and melatonin (12 papers), Bipolar Disorder and Treatment (11 papers), Treatment of Major Depression (11 papers), Schizophrenia research and treatment (10 papers) and Cholinesterase and Neurodegenerative Diseases (10 papers). The work is most often cited by research in Endocrine and Autonomic Systems (1.1k citations), Psychiatry and Mental health (2.1k citations), Biological Psychiatry (349 citations), Cognitive Neuroscience (1.4k citations) and Physiology (1.9k citations). Andrew Satlin has collaborated with scholars based in United States, United Kingdom and Sweden. Frequent co-authors include Ladislav Volicer, David G. Harper, Edward G. Stopa, Rachel Goldstein, Ann C. McKee, Hui Fang, Perry F. Renshaw, J. Alex Becker, Jack Zhang and B.L. Holman. Their work appears in journals such as Alzheimer s & Dementia, American Journal of Psychiatry, Schizophrenia Bulletin, American Journal of Geriatric Psychiatry and CNS Spectrums.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact